Boryung to physically split ETC business, turning it into an unlisted subsidiary
Predicted impact: Medium
Physical split of ETC business into unlisted subsidiary; restructuring of a business worth about 1/3 of last year's revenue unknown.
Boryung보령
003850 · KOSPI · ₩003850 · 보령
₩8,350▼ ₩50 (0.60%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y −5.54%
- Market cap
- ₩716B
- Enterprise value
- ₩899B
- P/E
- 5.9×
- P/B
- 0.8×
- Dividend yield
- 1.9%
- ROE
- 13.5%
- Net margin
- 11.4%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−22.7% from the high
₩7,410Today: ₩8,350 – ₩8,500₩10,800
Returns
- 1W−1.1%
- 1M+1.0%
- 3M+10.3%
- 6M−17.2%
- YTD−7.3%
- 1Y−5.5%
- Volume today
- 40,643
- 0.6× the 20-day average
- Traded today
- ₩341M
- Listed shares
- 85,787,207
- EPS (12 months)
- ₩1,406
- Earnings yield 16.8%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 36 of 100 (50 is a normal day for this stock).
- SentimentMixedNews: Restructuring and partnership news are mixed, with no clear positive or negative direction. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat0.8% over the last month; the price is below its 20-day average.
- News impactSome10 news items and filings in two weeks; 0 rated high impact, 3 medium.
Signals describe activity, not recommendations. Not financial advice.
Boryung stock overview
Boryung (보령, KRX: 003850) is listed on KOSPI, in the Biotech & Pharma sector. Boryung is a Korean pharmaceutical company focused on profitability and sustainable growth, pursuing its own-manufactured products and a stable portfolio of chronic-disease treatments. Its shares closed at ₩8,350 on Oct 28, 2026, down 0.60% on the day, giving it a market value of ₩716B.
Key facts
- Market cap
- ₩716B
- Sector
- Biotech & Pharma
- Latest price change
- −0.60%
- As of
- Oct 28, 2026
- Main business
- Boryung is a Korean pharmaceutical company focused on profitability and sustainable growth, pursuing its own-manufactured products and a stable portfolio of chronic-disease treatments.
Quick answers about Boryung
- What does Boryung do?
- Boryung is a Korean pharmaceutical company focused on profitability and sustainable growth, pursuing its own-manufactured products and a stable portfolio of chronic-disease treatments. Its main businesses include prescription drugs for hypertension and dyslipidemia (led by the Canaf family), oncology, diabetes, CNS and renal care, and specialty care, along with over-the-counter brands such as Gelfos and Yonggaksan. It also acquires established legacy brands, and it operates domestically with manufacturing facilities in Ansan and Yesan.
- What is the market cap of Boryung?
- The market capitalisation of Boryung was ₩716B at the close on Oct 28, 2026.
- Who are the largest shareholders of Boryung?
- According to the latest official filings, the largest reported holders are Boryung Holdings (64.88%, as of Sep 21, 2026); National Pension Service (4.12%, as of Apr 1, 2026); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (0.57%, as of Jul 31, 2026).
- When is the next earnings report from Boryung?
- Korean companies rarely announce results dates in advance. Based on when Boryung filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Boryung?
- Yes. The National Pension Service held 4.12% of Boryung shares as of Apr 1, 2026.
Company profile
Boryung is a Korean pharmaceutical company focused on profitability and sustainable growth, pursuing its own-manufactured products and a stable portfolio of chronic-disease treatments. Its main businesses include prescription drugs for hypertension and dyslipidemia (led by the Canaf family), oncology, diabetes, CNS and renal care, and specialty care, along with over-the-counter brands such as Gelfos and Yonggaksan. It also acquires established legacy brands, and it operates domestically with manufacturing facilities in Ansan and Yesan.
Written by AI from the company's latest annual report.
- Korean name
- 보령
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 김정균
- Founded
- Nov 1963
- Listed
- Oct 1988
- Listed shares
- 85,787,207
- Fiscal year ends
- Month 12
- Website
- www.boryung.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent news
Boryung partners with Japan's Kyushu Aerospace Center on space life sciences
Predicted impact: Low
Space life sciences partnership MOU with no disclosed financial size; routine collaboration news.
Boryung Signs Space Research MOU With DLR
Predicted impact: Low
Space research MOU with DLR; no financial size disclosed, routine partnership news.
Recent filings
See all- Results of Extraordinary Shareholders' MeetingOct 28, 2026
- Treasury share sale decisionOct 28, 2026
- Investor relations (IR) eventOct 22, 2026
- Preliminary earnings (consolidated)Oct 22, 2026
- Reference Document for Proxy Solicitation of Voting RightsOct 13, 2026
Titles in Korean until English translations are added.
Also known as: Boryung / 보령 / 003850 / KRX:003850
Source: KRX statistical information